Journal
JOURNAL OF PEPTIDE SCIENCE
Volume 22, Issue 1, Pages 4-27Publisher
WILEY
DOI: 10.1002/psc.2836
Keywords
solid-phase peptide synthesis; Fmoc; tBu; aspartimide; peptide thioester; post-translational modification; protecting group; racemisation
Funding
- Medical Research Council [MC_U117592730] Funding Source: Medline
- MRC [MC_U117592730] Funding Source: UKRI
Ask authors/readers for more resources
Today, Fmoc SPPS is the method of choice for peptide synthesis. Very-high-quality Fmoc building blocks are available at low cost because of the economies of scale arising from current multiton production of therapeutic peptides by Fmoc SPPS. Many modified derivatives are commercially available as Fmoc building blocks, making synthetic access to a broad range of peptide derivatives straightforward. The number of synthetic peptides entering clinical trials has grown continuously over the last decade, and recent advances in the Fmoc SPPS technology are a response to the growing demand from medicinal chemistry and pharmacology. Improvements are being continually reported for peptide quality, synthesis time and novel synthetic targets. Topical peptide research has contributed to a continuous improvement and expansion of Fmoc SPPS applications. Copyright (c) 2015 European Peptide Society and John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available